Drug Profile
Isaralgagene civaparvovec - Sangamo Therapeutics
Alternative Names: ST 920Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Sangamo Therapeutics
- Class Gene therapies
- Mechanism of Action Alpha-galactosidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Fabry's disease
Most Recent Events
- 13 Mar 2024 Isaralgagene civaparvovec - Sangamo Therapeutics is available for licensing as of 13 Mar 2024. https://www.sangamo.com/programs/#collaborations
- 13 Mar 2024 Isaralgagene civaparvovec - Sangamo Therapeutics receives Priority Medicine (PRIME) status for Fabry's disease in Europe before March 2024
- 13 Mar 2024 Isaralgagene civaparvovec - Sangamo Therapeutics receives Regenerative Medicine Advanced Therapy (RMAT) status for Fabry's disease in USA before March 2024